HeartFlow Logo

PRECISE Trial
Rewrites the
Patient Pathway

Helping physicians get the right patient,
the right care at the right time.

This image is not an accurate representation of the HeartFlow product

The PRECISE Trial

It’s confirmed. The Precision Pathway recognized in the AHA/ACC guidelines — centered around Coronary CTA+FFRCT — is superior to Traditional Testing, which prioritizes functional (stress) testing and Invasive Coronary Angiography (ICA).1

A closer look at the PRECISE Trial

Webinar: This panel of leading experts discusses insights from the PRECISE Trial 1-Year data, how the findings relate to the 2021 AHA/ACC Chest Pain Guidelines, and what the data tell us about different strategies for the evaluation and diagnosis of coronary artery disease. Featuring Dr. Pamela S. Douglas, Dr. Maros Ferencik, and Dr. Gregg W. Stone

1-Year Primary Endpoint Results

The Precision Pathway, centered around CCTA+FFRCT, achieved its primary endpoint by significantly reducing the composite of all-cause death, nonfatal MI, or catheterization without obstructive disease relative to Traditional Testing at 1 year.


Key Findings

Precision Pathway compared to Traditional Testing:

65
Global Sites
2,103
Patients
Adjudicated
Core Lab, CEC2
Precision Pathway
Risk scoring to defer testing for low-risk patients.3
CCTA with selective FFRCT4 for elevated risk patients.
Traditional Testing
Functional testing (stress nuclear and stress echo) and Invasive Coronary Angiography (ICA).

More accurate non-invasive diagnosis



Fewer unnecessary tests

Reduced long-term risk by increasing preventive therapies5


Download the Data Sheet

The PRECISE Trial Design

Patients with non-acute chest pain or the equivalent requiring testing for suspected CAD.

No history of Obstructive CAD or CAD testing < 1 year: N=2103

Randomized into one of two pathways.
Randomization stratified by site, PROMISE Minimal Risk Score (Low Risk vs. Elevated Risk), and intended first test (if randomized to Traditional Testing).

All subsequent care and testing decisions made by site clinician.
Guideline-directed medical management recommended for all.

Primary Endpoint (1 year)
Death, Nonfatal MI, Cath without obstructive CAD

Secondary Endpoints
Death, Nonfatal MI, Unplanned CV Hospitalizations, Radiation, Preventive Medication Use, Cath Yield, Resource Use, Quality of Life


Download the Data Sheet

REFERENCES

  1. Douglas, et al. The PRECISE Trial. Presented at AHA Scientific Sessions 2022. Clinical Events Committee (CEC)
  2. Clinical Events Committee (CEC)
  3. Patient risk was determined using the PROMISE Minimal Risk Score. PROMISE variables include: age, sex, ethnicity, smoking history, diabetes mellitus, dyslipidemia, family history of premature coronary artery disease, hypertension, symptoms related to stress and high-density lipoprotein (HDL) concentration.
  4. For stenoses 30-90%
  5. Joshi, et al. JAMA 2021.

173961488 v2